Literature DB >> 22759751

TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.

Doriane A Gouas1, Stphanie Villar, Sandra Ortiz-Cuaran, Pénélope Legros, Gilles Ferro, Gregory D Kirk, Olufunmilayo A Lesi, Maimuna Mendy, Ebrima Bah, Marlin D Friesen, John Groopman, Isabelle Chemin, Pierre Hainaut.   

Abstract

In regions with high prevalence of chronic hepatitis B virus (HBV) infection and dietary aflatoxin B(1) (AFB(1)) exposure, hepatocellular carcinomas (HCCs) often contain TP53 mutation at codon 249 (R249S). Furthermore, a C-terminal truncated HBx protein expressed from hepatocyte integrated HBV is associated with HCC development. This study evaluates the association between R249S and HBX status in relation to HCC in West African population. HBX (complete or 3'-truncated) and HBS genes were assessed by PCR in cell-free DNA (CFDNA) from plasma of subjects recruited in a hospital-based case-control study (325 controls, 78 cirrhotic patients and 198 HCC cases) conducted in The Gambia. These samples had been previously analyzed for R249S and HBV serological status. Complete HBX sequence was frequently detected in CFDNA of HCC-R249S positive (77%, 43/56) compared with HCC-R249S-negative cases (44%, 22/50). Conversely, the proportion of 3'-truncated HBX gene was significantly higher in HCC-R249S negative than positive cases (34%, 17/50, compared with 12%, 7/56) (χ(2) = 12.12; P = 0.002; distribution of R249S negative and positive according to HBX status). Occult HBV infection (detected by PCR) was present in 24% of HCC previously considered as negative by HBV serology. Moreover, HBV mutation analysis revealed that double mutation at nucleotides 1762(T)/1764(A) was associated with diagnosis of cirrhosis or HCC {cirrhosis: odds ratio (OR): 9.50 [95% confidence interval (CI) 1.50-60.11]; HCC: OR: 11.29 [95% CI 2.07-61.47]}. These findings suggest that in HCC from The Gambia, complete HBX sequences are often associated with the presence of TP53 R249S mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22759751      PMCID: PMC3388490          DOI: 10.1093/carcin/bgs068

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  45 in total

1.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

2.  Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues.

Authors:  H Tu; C Bonura; C Giannini; H Mouly; P Soussan; M Kew; P Paterlini-Bréchot; C Bréchot; D Kremsdorf
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

Review 3.  Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis.

Authors:  Mark A Feitelson; Jungmin Lee
Journal:  Cancer Lett       Date:  2006-12-22       Impact factor: 8.679

Review 4.  Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 4.029

5.  Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.

Authors:  Helene Norder; Anne-Marie Couroucé; Pierre Coursaget; José M Echevarria; Shou-Dong Lee; Isa K Mushahwar; Betty H Robertson; Stephen Locarnini; Lars O Magnius
Journal:  Intervirology       Date:  2004       Impact factor: 1.763

Review 6.  Hepatitis B virus genotypes.

Authors:  Anna Kramvis; Michael Kew; Guido François
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

7.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria.

Authors:  Joseph C Forbi; Gilberto Vaughan; Michael A Purdy; David S Campo; Guo-liang Xia; Lilia M Ganova-Raeva; Sumathi Ramachandran; Hong Thai; Yury E Khudyakov
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

9.  Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa.

Authors:  C P Wild; G J Hudson; G Sabbioni; B Chapot; A J Hall; G N Wogan; H Whittle; R Montesano; J D Groopman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1992 Mar-Apr       Impact factor: 4.254

10.  Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma.

Authors:  P Paterlini; K Poussin; M Kew; D Franco; C Brechot
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more
  20 in total

1.  Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.

Authors:  Jingjing Jiao; Weibo Niu; Ying Wang; Keith Baggerly; Yuanqing Ye; Xifeng Wu; Dewitt Davenport; Jose Luis Almeda; Monica M Betancourt-Garcia; R Armour Forse; Heather L Stevenson; Gordon P Watt; Joseph B McCormick; Susan P Fisher-Hoch; Laura Beretta
Journal:  Cancer Prev Res (Phila)       Date:  2017-10-31

Review 2.  Problem of hepatocellular carcinoma in West Africa.

Authors:  Nimzing G Ladep; Olufunmilayo A Lesi; Pantong Mark; Maud Lemoine; Charles Onyekwere; Mary Afihene; Mary Me Crossey; Simon D Taylor-Robinson
Journal:  World J Hepatol       Date:  2014-11-27

Review 3.  The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Authors:  Jessica A Howell; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-11-30

Review 4.  p53 in liver pathologies-taking the good with the bad.

Authors:  Meital Charni; Noa Rivlin; Alina Molchadsky; Ronit Aloni-Grinstein; Varda Rotter
Journal:  J Mol Med (Berl)       Date:  2014-11-19       Impact factor: 4.599

Review 5.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

Review 6.  Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.

Authors:  Ashraf Ali; Hany Abdel-Hafiz; Mohd Suhail; Amany Al-Mars; Mohammad Khalid Zakaria; Kaneez Fatima; Sultan Ahmad; Esam Azhar; Adeel Chaudhary; Ishtiaq Qadri
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 7.  Key role of hepatitis B virus mutation in chronic hepatitis B development to hepatocellular carcinoma.

Authors:  Xin Zhang; Hui-Guo Ding
Journal:  World J Hepatol       Date:  2015-05-28

Review 8.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

Review 9.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

10.  Epigenetic influences in the aetiology of cancers arising from breast and prostate: a hypothesised transgenerational evolution in chromatin accessibility.

Authors:  Francis L Martin
Journal:  ISRN Oncol       Date:  2013-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.